Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models

  • As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's ELDN AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non-human primates before starting a Phase 2 trial in renal transplantation in the U.S.
  • Hence, Eledon plans to initiate an evaluation of AT-1501 in a standard non-human primate model of renal transplantation, which is expected to be completed by late 2022.
  • No significant drug-related safety signals with AT-1501 have been identified to date. This change in development strategy is not due to any specific event or data, the company said.
  • AT-1501, the company's lead candidate, is an anti-CD40L antibody with a high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • SVB Leerink analyst Thomas Smith maintains Eledon's Outperform rating and lowers the price target from $34 to $33.
  • Price Action: ELDN shares are up 7.1% at $11.48 in the premarket trading on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareReiterationFDAAnalyst RatingsGeneralBriefsRenal Diseases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!